BCRX vs MELI · rev $374.7M vs P/E 43, rev $19.01B
BioCryst Pharmaceuticals Inc (BCRX) versus MercadoLibre Inc. (MELI) — a side-by-side from cached financials, not a winner call.
BioCryst Pharmaceuticals Inc (BCRX) is a drug manufacturers - specialty & generic company listed on US.
MercadoLibre Inc. (MELI) is a internet retail company listed on NASDAQ.
Latest reported BCRX revenue for 2026-06-30 was $374.7M. Net income was -$643.4M. BCRX currently screens at market cap $1.83B.
Latest reported MELI revenue for 2026-06-30 was $19.01B. Net income was $883.0M. MELI currently screens at market cap $82.73B and trailing P/E 43.1.
BCRX currently screens at market cap $1.83B. MELI currently screens at market cap $82.73B and trailing P/E 43.1.
Not investment advice. Open the BCRX and MELI stock pages for the full models.
Not investment advice.